SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044. The stock peaked at ₹186 but fell to ₹156.50 during trading on the BSE.

Sun Pharma's shares experienced a 0.47 per cent decline, trading at Rs 1,659.80, alongside the sharper fall in SPARC shares ...